Alnylam Pharmaceuticals Inc. (ALNY) is in the Pharma Industry

• Sort by

• Glaxo to Buy Biotech Sirtris in $720 Mln Deal

  By Ransdell Pierson NEW YORK (Reuters UK) - GlaxoSmithKline GSK said on Tuesday it had agreed to buy biotechnology company Sirtris Pharmaceuticals Inc SIRT for $720 million (360.69 million pounds) in cash, in hopes its medicines that modulate an aging-related family of enzymes will be...

  News items 2008-04-22

  Tags: Glaxo, Type 2, Regulus, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc., Sirtris Pharmaceuticals Inc.

• Glaxo Boosts Biotech With Regulus Deal

  By Ben Hirschler LONDON (Reuters UK) - GlaxoSmithKline GSK boosted its position in biotech on Thursday by signing a deal that could be worth up to $600 million (303 million pounds) with Regulus Therapeutics, taking it into the hot area of RNA technology. The tie-up covers...

  News items 2008-04-17

  Tags: RNA, Inflammation, Regulus Therapeutics, MicroRNAs, Biotechnology, Alnylam Pharmaceuticals Inc., GlaxoSmithKline Plc., Isis Pharmaceuticals Inc.

Additional Resources

• Regulus Therapeutics Exclusively Licenses Intellectual Property from Stanford University Relating to microRNA Antagonists to Treat Inflammatory Diseases

  CAMBRIDGE, Mass. & CARLSBAD, Calif. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) formed to discover, develop, and commercialize microRNA miRNA therapeutics, announced today that it has obtained exclusive rights from Stanford University to worldwide patent applications covering methods...

  Articles 2008-05-06

• Alnylam to Webcast Conference Call Discussing First Quarter 2008 Financial Results

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it will report financial results for the first quarter of 2008 on Thursday, May 8, 2008, after the U.S. financial markets close. Management will provide an update on the company, discuss first...

  Articles 2008-05-02

• Alnylam to Webcast Presentation at the Deutsche Bank 33rd Annual Health Care Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Deutsche Bank 33rd Annual Health Care Conference on Tuesday, May 6, 2008, at 9:30 a.m. ET at the InterContinental Hotel in Boston, Mass. A...

  Articles 2008-04-30

• Alnylam and Collaborators at MIT Publish Research on the Discovery of 'Lipidoids', a Novel Class of Lipid-Based Molecules for the Delivery of RNAi Therapeutics

  New Findings Published in Nature Biotechnology Demonstrate Use of "Lipidoids" to Achieve Systemic Delivery of RNAi Therapeutics in Multiple Pre-Clinical Models CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a new study in Nature Biotechnology by Alnylam scientists...

  Articles 2008-04-28

• Alnylam and Collaborators Publish Research on the Immunostimulatory Properties and Mechanisms of Certain siRNAs in Mammalian Cells

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication of a study in the Journal of Interferon & Cytokine Research by scientists at Alnylam Europe now Roche Kulmbach, and collaborators, further delineating the mechanisms whereby some siRNAs can trigger immunostimulatory effects in...

  Articles 2008-04-28

• Alnylam to Webcast Presentation at the Morgan Stanley Global Healthcare Unplugged Conference

  CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at the Morgan Stanley Global Healthcare Unplugged Conference on Friday, May 2, 2008, at 9:50 a.m. ET at The Ritz-Carlton in Key Biscayne, Florida. A live...

  Articles 2008-04-25

• 17th Annual Conference Hosts Successful Biotech Entrepreneurs, Big Pharma Leaders, Policy Makers and Investors as Featured Speakers and on Panels

  RESEARCH TRIANGLE PARK, N.C. -- Four well-respected leaders will provide the featured presentations at Biotech 2008, the 17th annual regional biotech conference sponsored by the Council for Entrepreneurial Development. The event, held on Monday and Tuesday, May 19 and 20, will be host to Frederick Frank, vice chairman and director...

  Articles 2008-04-24

• GlaxoSmithKline and Regulus Therapeutics Form Strategic Alliance To Develop MicroRNA Targeted Therapeutics to Treat Inflammatory Diseases

  Companies Announce Significant microRNA Therapeutics Collaboration LONDON & PHILADELPHIA & CARLSBAD, Calif. -- GlaxoSmithKline GSK and Regulus Therapeutics LLC Regulus today announced a worldwide strategic alliance to discover, develop and market novel microRNA-targeted therapeutics to treat inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Regulus is...

  Articles 2008-04-17

• Regulus Therapeutics to Host Conference Call to Discuss GlaxoSmithKline Alliance

  CARLSBAD, Calif. & CAMBRIDGE, Mass. -- Regulus Therapeutics LLC, a joint venture between Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that it will hold a conference call this morning, Thursday, April 17, at 8:00 a.m. ET to discuss its new alliance with GlaxoSmithKline. ...

  Articles 2008-04-17

• Alnylam Initiates Phase II Trial to Evaluate Safety and Tolerability of ALN-RSV01 in Adult Lung Transplant Patients Naturally Infected with Respiratory Syncytial Virus Infection

  - Secondary Objectives Include Measurements of Anti-viral Activity - CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today it has initiated a Phase II clinical trial to assess the safety and tolerability of aerosolized ALN-RSV01 versus placebo in adult lung transplant patients...

  Articles 2008-04-09

• Tekmira Pharmaceuticals Releases 2007 Audited Operating Results

  Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) today released its 2007 audited operating results, including a summary of 2007 corporate and product development achievements and an update of objectives for 2008. The Company said key achievements in 2007 included a corporate restructuring and an equity financing that strengthened the Company's balance...

  Articles 2008-03-31

• Alnylam Presents Pre-clinical Data from Hypercholesterolemia, Liver Cancer, Ebola, and Progressive Multifocal Leukoencephalopathy Programs at RNAi Keystone Symposium

  New Data Highlight Broad Applications of RNAi Therapeutics and Continued Progress in Advancing Pipeline of Innovative Medicines New Results Also Document Significant Advancements in Systemic Delivery of RNAi Therapeutics CAMBRIDGE, Mass. -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that it...

  Articles 2008-03-31

• Progressive Following on alnylam pharmaceuticals inc.

  M2 PRESSWIRE-31 March 2008-The Street Corner: Progressive Following on Alnylam Pharmaceuticals IncC1994-2008 M2 COMMUNICATIONS LTD RDATE:31032008 Streetinvesting.com has now resumed our progressive review of Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) as it opened up $0.51 on average volume early trading Monday,...

  Articles 2008-03-31

• Alnylam Forms New Agreement with Tekmira Related to the Planned Tekmira-Protiva Business Combination

  Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create New Company Focused on RNAi Delivery and Therapeutics New Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics Alnylam to Invest $5 Million in New Combined Company ...

  Articles 2008-03-30

• Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics

  Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX: TKM) and Protiva Biotherapeutics Inc. announced today that they have signed a Share Purchase Agreement under which the two Vancouver-based companies will combine their businesses by Tekmira purchasing the outstanding equity of privately owned Protiva. The combined company, which will retain the name Tekmira, will...

  Articles 2008-03-30

• Tekmira Pharmaceuticals Releases 2007 Audited Operating Results.

  VANCOUVER, BRITISH COLUMBIA, Mar 30, 2008 Marketwire via COMTEX -- Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX:TKM) today released its 2007 audited operating results, including a summary of 2007 corporate and product development achievements and an update of objectives for 2008. The Company said...

  Articles 2008-03-30

• Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics; Alnylam and Roche to Invest $10 million in Combined Company.

  VANCOUVER, BRITISH COLUMBIA, Mar 30, 2008 Marketwire via COMTEX -- Tekmira Pharmaceuticals Corporation ("Tekmira") (TSX:TKM) and Protiva Biotherapeutics Inc. announced today that they have signed a Share Purchase Agreement under which the two Vancouver-based companies will combine their businesses by Tekmira purchasing the outstanding equity...

  Articles 2008-03-30

• Alnylam Grants Shanghai GenePharma License to Kreutzer-Limmer Patents for the RNA Interference Research Products Market

  CAMBRIDGE, Mass. & SHANGHAI, China -- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, and Shanghai GenePharma Co., Ltd, a leading siRNA supplier in China, announced today that Alnylam has granted Shanghai GenePharma a non-exclusive world-wide license to manufacture and provide RNAi research products and services under the...

  Articles 2008-03-20